Crohn's disease 1 , 2 and ulcerative colitis, the two main types of chronic inflammatory
bowel disease, are multifactorial conditions of unknown aetiology. A susceptibility locus for …

Background & Aims : Adherent-invasive Escherichia coli (AIEC) pathovar has been identified
in the intestinal mucosa of patients with Crohn’s disease (CD). AIEC reference strain LF82 …

Background The comparative efficacy and safety of infliximab and azathioprine therapy alone
or in combination for Crohn's disease are unknown. Methods In this randomized, double-…

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor
α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods Two …

The discovery of a series of genetic and serological markers associated with disease
susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an …

Background & Aims: This study evaluated the efficacy and safety of adalimumab, a fully
human, anti–tumor necrosis factor monoclonal antibody administered subcutaneously, in the …

Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized, …

Background The efficacy of vedolizumab, an α 4 β 7 integrin antibody, in Crohn's disease is
unknown. Methods In an integrated study with separate induction and maintenance trials, we …

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with increasing
incidence worldwide. Crohn's disease might result from a complex interplay between …

BACKGROUND: Healing of mucosal lesions appears to offer significant benefit and is an
important end point in clinical trials of treatment for Crohn's disease. The only validated …